In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against Prem Watsa’s other long-term stock picks. Prem Watsa is a Canadian billionaire, entrepreneur ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...

Rumours that Merck was planning a $30 billion-plus takeover bid for Seagen have so far come to nothing, but it did complete a deal to buy VelosBio for $2.75 billion in late 2020 to add an ADC ...

Merck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) has approved two new HIV-1 medicines: Delstrigo and Pifeltro.

Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in its portfolio. "Keytruda has ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing Consortium aimed at pioneering new advances in how medicines are produced.

Frespaciguat is under clinical development by Merck and currently in Phase II for Pulmonary Hypertension. According to GlobalData, Phase II drugs for Pulmonary Hypertension have a 58% phase transition ...